Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons with Global Deterioration Scale Stage 2 (Subjective Cognitive Decline with Impairment)

Manuscript Number: 

18-0341R1

Author(s): 
Munther Alshalabi, Fauzia Arain, Stefanie Auer, Francoise Guillo Benarous, Rafael Blesa, Istvan Boksay, Maja Buj, Serge Gauthier, James Golomb, Mudasar Hassan, Sunnie Kenowsky, Alan Kluger, Karyn Marsh, Arjun V. Masurkar, Isabel Monteiro, Maryam Noroozian, Thet Oo, Laura A. Rabin, Julia A. Rao, Barry Reisberg, Martin Sadowski, Jaspreet Sangha, Naveed Shaikh, Yongzhao Shao, Melanie B. Shulman, Ma Belén Sánchez-Saudinós, Carol Torossian, Anaztasia Ulysse, Alok Vedvyas, Thomas Wisniewski, Yian Zhang, Mony J. de Leon

Disclosures

Munther Alshalabi

  • Nothing to Disclose

Fauzia Arain

  • Nothing to Disclose

Stefanie Auer

  • Nothing to Disclose

Francoise Guillo Benarous

  • Nothing to Disclose

Rafael Blesa

  • Consulting Fees:
    Nutricia, Lilly

Istvan Boksay

  • Nothing to Disclose
  • Nothing to Disclose

Maja Buj

  • Nothing to Disclose

Mony J. de Leon

  • Nothing to Disclose

Serge Gauthier

  • Consulting Fees:
    Member of a scientific advisory board for Axovant, Kalgene, Lilly, Lundbeck, TauRx. Member of DSMB for ADCS, ATRI, API, Eisai
    Grants
    • Agency: 
      NIH
      Dates: 
      2014-2020

James Golomb

  • Nothing to Disclose

Mudasar Hassan

  • Nothing to Disclose

Sunnie Kenowsky

  • Consulting Fees:
    I am a managing member and part owner of Cure Medical, a medical devise company.
    Lecture Fees:
    I am paid by the New York University Wellness Center through the Department of Psychiatry to give community lectures on caregiving, dementia, aging and memory and various other topics to their corporate clients, i.e. Rockefeller University, Credit Suisse, etc. I am typically paid $175 for an hour presentation. I usually present 3 to 4 community lectures per year.

Alan Kluger

  • Nothing to Disclose

Karyn Marsh

  • Nothing to Disclose

Arjun V. Masurkar

  • Nothing to Disclose

Isabel Monteiro

  • Nothing to Disclose

Maryam Noroozian

  • Nothing to Disclose

Thet Oo

  • Nothing to Disclose

Laura A. Rabin

  • Nothing to Disclose

Julia A. Rao

  • Nothing to Disclose

Barry Reisberg

  • Patents/Royalties
    Barry Reisberg, M.D., is the developer and copyright holder of the Global Deterioration Scale (GDS), the Brief Cognitive Rating Scale (BCRS), the Functional Assessment Staging (FAST) and the Behavioral Pathology in Alzheimer’s Disease (BEHAVE-AD) instruments which were used in the present investigations and/or, in related investigations, described herein. These instruments were provided at no charge for all of the studies described and/or cited herein. Dr. Reisberg also notes that he receives, or has recently received, royalty payments for one or more of the above assessment instruments from Encompass Home Health, Genesis Health Care LLC, Point Click Care and Cha Pharmaceuticals. Dr. Reisberg has also received, royalty payments from Special Commerce Corporation (SCC) Publishing and Simon and Schuster in the past year. Although not related to this study, Dr. Reisberg also notes that he has received royalty fees from MedAvante-Pro-Phase, Inc. and consulting fees from the U.S. Federal Trade Commission, in the past year.
    Grants
    • Agency: 
      GE Healthcare
      Dates: 
      2018

Martin Sadowski

  • Consulting Fees:
    Consulting fees from Alzheon Inc. within the past 12 mos.
    Patents/Royalties
    Patent No. US 8,658,677 B2 licensed to Aria Neuroscience Inc.
    Grants
    • Agency: 
      Biogen Inc. (NYU Site PI for clinical trials Engage and Tango)
      Dates: 
      11/15-01/22
    • Agency: 
      Novartis Pharmaceuticals Corp. (NYU Site PI for clinical trials Generations I and II)
      Dates: 
      12/16-8/25
    • Agency: 
      Suven Life Sciences Ltd. (NYU Site PI for SUNV-502 Clinical Trial)
      Dates: 
      7/16-3/21
    • Agency: 
      Merck Sharp & Dohme Corp. (NYU Site PI for SCH900931 and
      Dates: 
      08./13-06/19
    • Agency: 
      Neurotrack Technologies Inc. (Individual research grant)
      Dates: 
      06/14-09/19
    • Agency: 
      Janssen Research and Development (Individual research grant)
      Dates: 
      12/15-12/18

Ma Belén Sánchez-Saudinós

  • Nothing to Disclose

Jaspreet Sangha

  • Nothing to Disclose

Naveed Shaikh

  • Nothing to Disclose

Yongzhao Shao

  • Nothing to Disclose

Melanie B. Shulman

  • Nothing to Disclose

Carol Torossian

  • Nothing to Disclose

Anaztasia Ulysse

  • Nothing to Disclose

Alok Vedvyas

  • Nothing to Disclose

Thomas Wisniewski

  • Patents/Royalties
    I am an inventor on a number of patents that are unrelated to the subject matter of this manuscript.

Yian Zhang

  • Nothing to Disclose